Impact of Body Mass Index on Long-Term All-Cause Mortality after Percutaneous Coronary Intervention in African-Americans
|
|
- Marilyn Burke
- 5 years ago
- Views:
Transcription
1 Original Contribution Impact of Body Mass Index on Long-Term All-Cause Mortality after Percutaneous Coronary Intervention in African-Americans Shyam Poludasu, MD, Erdal Cavusoglu, MD, Waqas Khan, MD, Jonathan D. Marmur, MD ABSTRACT: Background. Studies on body mass index (BMI) and post-percutaneous coronary intervention (PCI) outcomes have suggested an obesity paradox (lower post- PCI mortality rates in obese patients compared to patients of normal weight). Hypothesis. We assessed the hypothesis that BMI is an independent predictor of post-pci long-term mortality in African-Americans. Methods. We evaluated 777 patients (146 with normal BMI [BMI >18.5 to < 25 kg/m 2 ], 261 overweight patients [BMI 25 to < 30 kg/m 2 ], and 370 obese patients [BMI 30 kg/m 2 ]) who underwent PCI during January 2003 to August Results. After a median follow up of 4 ± 1 years, the overall mortality rate was 10.5% (82 deaths). The survival rate was 84%, 90% and 92% in the normal BMI, overweight and obese groups, respectively (p = by log-rank test; hazard ratio relative to the obese group was 2.2 for the normal weight and 1.2 for the overweight groups). After adjustment for baseline clinical and procedural characteristics (age, smoking history, chronic renal insufficiency, end-stage renal disease, left main coronary artery intervention, preprocedure hemoglobin, left ventricular ejection fraction and successful PCI) using a Cox proportional hazards model, there was no significant difference in the long-term all-cause mortality rate among the three groups (p = 0.93). Conclusion. BMI does not appear to be an independent predictor of long-term mortality after PCI in African-Americans. J INVASIVE CARDIOL 2009;21:20 25 Key words: Body mass index, African-Americans, percutaneous coronary intervention Obesity is a well-established risk factor for coronary artery disease (CAD). 1 Accordingly, a higher number of patients with obesity are undergoing percutaneous coronary intervention (PCI). 2 Obese patients are assumed to have worse outcomes after PCI. However, recent studies 3,4 and a meta-analysis 5 have suggested an apparent protective effect of obesity on post-pci mortality. Because obesity would be predicted to increase the From SUNY Downstate Medical Center, Brooklyn, New York. The authors report no conflicts of interest regarding the content herein. Manuscript submitted July 14, 2008, provisional acceptance given September 8, 2008, final version accepted October 3, Address for correspondence: Jonathan D. Marmur, MD, FACC, SUNY Downstate Medical Center, Cardiology, 450 Clarkson Avenue, Box 1257, Brooklyn, NY jonathan@marmur.com likelihood of adverse outcomes, the term obesity paradox has been used if obese patients are found to have lower mortality compared to the non-obese group. 3,4 Obesity is a rapidly growing epidemic in the United States and African-Americans are disproportionately affected. Approximately 45% of African-Americans were reported to be obese in , compared to only 30.6% and 36.8% obese Caucasians and Hispanics, respectively. 6 The long-term mortality after PCI is unknown in this population subgroup. Accordingly, the present study evaluated the effect of body mass index (BMI) on long-term all-cause mortality in a cohort of African-American patients who underwent PCI at an inner city single-center institution. Methods Study cohort. This is a retrospective analysis of 777 consecutive African-American patients from our bolus-only glycoprotein IIb/IIIa (GPI) database and activated clotting time (ACT)-guided intravenous (IV) dalteparin dosing during PCI. We retrospectively analyzed 1397 (1001 consecutive patients during January 2003 to August 2004, 292 consecutive patients during December 2004 to August 2005 in two separate studies 7,8 on GPI bolus-only therapy during PCI, and 104 consecutive patients who underwent PCI with IV dalteparin from December 2005 to August 2006) 9 patients who underwent PCI at a single center. From this database we included all African- Americans in the current study. The first PCI occurring during this time period is taken as the index procedure. Patients without a valid social security number had to be excluded from the study, as the longer-term follow up was obtained using the Social Security Death Index. The hospital s institutional review board approved the study. Demographic data including height and weight of the patient, periprocedural and laboratory data were collected by reviewing charts and hospital records. The in-hospital events and the length of stay are also recorded. Patients with ST-segment elevation myocardial infarction (STEMI) were not treated with bolus-only GPI and therefore were excluded from the bolus-only GPI database. Periprocedural medication. All patients were loaded with aspirin 325 mg and clopidogrel mg prior to PCI. All patients in our GPI bolus-only studies received an initial bolus of IV 40 units/kg unfractionated heparin (UFH) plus a bolus of GPI (0.25 mg/kg abciximab, 25 g/kg tirofiban or 180 g/kg x 2 eptifibatide) at the beginning of the intervention, which is 20 The Journal of Invasive Cardiology
2 BMI and Mortality after PCI in African-Americans Cumulative Survival Kaplan-Meier survival curves for normal weight, overweight and obese patients undergoing PCI Log-rank test p = BMI = > 30 kg/m 2 BMI = > 25 to < 30 kg/m 2 BMI = > 18.5 to < 25 kg/m Follow Up (days) Figure 1. Kaplan-Meier survival curves according to body mass index (BMI) divided as normal (> 18.5 to < 25 kg/m 2 ) overweight ( 25 to < 30 kg/m 2 ), and obese ( 30 kg/m 2 ). At 4 ± 1 years, the survival rate was 84% in the group with normal weight, 90% in the overweight group, and 92% in the obese group (p = by log-rank test). the standard practice at our institution. 7,8 If necessary, supplemental boluses of UFH were administered to achieve a target activated clotting time (ACT) of at least 200 seconds. In the ACT-guided IV dalteparin study, all patients received an initial IV bolus of 50 IU/kg of dalteparin. A GPI bolus at the beginning of the intervention was given at the discretion of the operator. Those patients who did not reach a target ACT with an initial bolus of dalteparin were given supplemental boluses as described previously. 9 The ACT was measured using the Hemochron device (ITC Technidyne Corp., Edison, New Jersey). Coronary intervention. Coronary interventional procedures were performed according to standard techniques via a femoral approach. The choice of drug-eluting stent (DES) or bare-metal stent (BMS) implantation was at the discretion of the operator. Femoral vascular closure devices (Angio-Seal, St. Jude Medical, Minnetonka, Minnesota, or Perclose, Perclose, Inc., Redwood City, California) were used unless contraindicated. Serial monitoring of cardiac biomarkers was performed every 8 hours for 24 hours after PCI, and hemoglobin levels were measured every 24 hours until the patient was discharged. At the time of discharge, all patients were instructed to take aspirin indefinitely. Clopidogrel was recommended for at least 1 month for the patients who received BMS and for at least 9 12 months for those who received DES. Follow up. We used all-cause mortality as our long-term outcome. The Social Security Death Index 10 was used to determine the time of death on April 24, Definitions. Body mass index was calculated as weight in kilograms divided by the square of the patient s height in meters (kg/m 2 ). Based on BMI, the study cohort was divided into normal (> 18.5 to < 25 kg/m 2 ), overweight ( 25 to <30 kg/m 2 ), and obese ( 30 kg/m 2 ). Hyperlipidemia was diagnosed in patients who received lipidlowering medication or who had a history of low-density lipoprotein (LDL) > 130 mg/dl. Smoking was defined as the inhaled use of cigarettes, cigars or pipes in any quantity in the last 2 weeks prior to the procedure. Left ventricular dysfunction was defined as left ventricular ejection fraction (LVEF) < 50% on echocardiography or coronary angiography in the past. Chronic renal insufficiency (CRI) was defined as patients with creatinine levels > 1.5 mg/dl, but who were not dependent on chronic dialysis. Patients were considered to have end-stage renal disease (ESRD) if they were dependent on chronic dialysis. Non-STsegment elevation myocardial infarction (NSTEMI) was defined as chest pain and enzymatic evidence of myocardial infarction (MI), but without ST-segment elevation on the presenting electrocardiogram (ECG). Unstable angina pectoris was defined according to the classification scheme based on the guidelines of the American College of Cardiology/American Heart Association. 11 Post-PCI MI was defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria. 12 A new MI was defined by biochemical or ECG criteria: the MB isoform of creatinine kinase (CK-MB) at least three times the upper limit of the normal range in at least one blood sample, or the finding of abnormal Q-waves 2 contiguous leads. For patients with a recent MI who had an elevated CK-MB level before the procedure, a value of more than three times the upper limit of normal and at least 50% above the baseline value was required to meet the definition. Bleeding was defined according to the Randomized Evaluation in the PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) criteria. 13 Although many studies in the cardiovascular literature used a definition of bleeding based on the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleeding, 14 in the current study, we defined bleeding based on the REPLACE-2 criteria, as these definitions are more sensitive and were well validated as predictors of higher mortality on long-term follow up. 15 Major bleeding was defined as either any intracranial, intraocularor, retroperitoneal or clinically overt bleeding with a drop of hemoglobin by 3 g/dl, or any drop of hemoglobin by 4 g/dl, or the transfusion of 2 more units of packed red blood cells. Minor bleeding was defined as clinically overt bleeding not meeting the above criteria. Thrombocytopenia was defined as a fall in the platelet count below 100,000/ l, or a decrease by 25% below baseline values, in the event the initial platelet count was less than 100,000/ l. Statistical analysis. Continuous variables are presented as mean ± standard deviation (SD). Categorical variables are presented as percentages. The chi-square test was used to compare the differences between categorical variables. The Kruskal Wallis test was used to compare continuous variables without a normal distribution. For in-hospital outcomes, logistic regression analyses were Vol. 21, No. 1, January
3 POLUDASU, et al. Table 1. Baseline characteristics. Normal BMI (n = 146) Over weight (n = 261) (> 18.5 to < 25 kg/m 2 ( 25 to < 30 kg/m 2 ) Obese (n = 370) ( 30 kg/m 2 ) Age (mean ± SD in years) 66 ± ± ± 10 < Females, n (%) 83 (56.8) 142 (54.4) 146 (39.5) < Indication, n (%) NSTEMI 26 (17.8) 45 (17.2) 51 (13.8) 0.37 Unstable angina 66 (45.2) 97 (37.2) 151 (40.8) 0.28 Stable angina and others 54 (37) 121 (46.4) 170 (45.9) 0.13 Medical history, n (%) Hypertension 131 (89.7) 227 (87) 335 (90.5) 0.35 Diabetes mellitus 67 (45.9) 121 (46.4) 209 (56.5) LV dysfunction (LVEF < 50) 54 (37) 72 (28) 105 (28) 0.10 Smoking 49 (33.6) 82 (31.4) 101 (27.3) 0.30 Family history 28 (19.2) 65 (24.9) 119 (32.2) Previous CAD 74 (50.7) 154 (59) 201 (54.3) 0.24 CRI (creatinine > 1.5 mg/dl) 44 (30.1) 71 (27.2) 71 (19.2) 0.01 ESRD 13 (8.9) 14 (5.4) 16 (4.3) 0.12 Medications, n (%) Beta-blocker 114 (78.1) 218 (83.5) 298 (80.5) 0.38 Statin 119 (81.5) 207 (79.3) 306 (82.7) 0.60 ACE-inhibitor 97 (66.4) 191 (73.2) 260 (70.3) 0.35 GP IIb/IIIa inhibitor, n (%) 136 (93.2) 241 (92.3) 337 (91.1) 0.7 Abciximab 33 (22.6) 81 (31) 116 (31.4) 0.12 Eptifibatide 49 (33.6) 102 (39.1) 147 (39.7) 0.41 Tirofiban 54 (37) 59 (22.6) 74 (20) < Ejection fraction (mean ± SD) 48 ± ± ± Dalteparin during PCI, n (%) 12 (8.2) 23 (8.8) 36 (9.7) 0.84 BMI = body mass index; SD = standard deviation; NSTEMI = Non-ST-segment elevation myocardial infarction; CAD = coronary artery disease; CRI = chronic renal insufficiency; ESRD = end-stage renal disease; GP = glycoprotein conducted to assess the univariate effect of predictors of interest and the extent of confounding or interaction of these predictors with covariates statistically significant in univariate analysis. Event-free survival rates during the follow-up period were estimated by the Kaplan-Meier method and tested by the log-rank statistic. Multivariable Cox proportional-hazards regression modeling was used to adjust for the covariates that had significant impact (p < 0.05) on all-cause mortality in the study population. Sequential models were fit with the initial model including no covariates (unadjusted); the final model included covariates selected by step-wise methods that had significant impact on all-cause mortality. Covariates tested in a step-wise fashion in the multivariable Cox proportional-hazards regression model include age, gender, BMI, indication for the procedure (NSTEMI, unstable angina and stable angina), history of any medical problems (hypertension, diabetes mellitus, CAD, congestive heart failure, chronic renal insufficiency, end-stage renal disease), smoking history, family history of CAD, medications (beta-blockers, ACE-inhibitors and statins), type of platelet glycoprotein IIb/IIIa inhibitor used, LVEF, target coronary artery, number of diseased vessels, multivessel intervention, type of stent used, length and diameter of the stents used, percentage stenosis of the vessels, maximum ACT, successful PCI and in-hospital outcomes (post-pci MI, bleeding complications and thrombocytopenia). P-values < 0.05 were considered to indicate statistical significance. All statistical analyses are performed utilizing SPSS software Version 15.0 (SPSS, Inc., Chicago, Illinois). Results Baseline characteristics. The baseline characteristics are listed in Table 1 and procedural characteristics are presented in Table 2. There were 146 patients in the normal BMI arm, 261 patients in the overweight arm and 370 patients in the obese arm. Higher BMI groups had younger patients, fewer proportions of women, higher proportions of patients with diabetes, family history of CAD, fewer proportions of patients who received tirofiban during PCI and had higher mean LVEF (Table 1). In the procedural characteristics, higher BMI groups had a lower mean peak ACT (Table 2). In-hospital outcomes. The in-hospital outcomes are presented in Table 3. There was no difference in the in-hospital composite endpoint of death, non-fatal MI, repeat revascularization and bleeding complications (adjusted p = 0.86; covariates in the logistic regression model were NSTEMI, mean diameter of the stent, mean length of the stent and number of stents used). We did not perform a logistic regression analysis for the in-hospital individual complications due to a very low incidence of these complications, which might not yield meaningful results. However, the unadjusted non-fatal MI rate was lower in the normal BMI arm (2.1% in the normal BMI arm 22 The Journal of Invasive Cardiology
4 BMI and Mortality after PCI in African-Americans Table 2. Procedural characteristics. Normal BMI (n = 146) (> 18.5 to < 25 kg/m 2 Overweight (n = 261) ( 25 to < 30 kg/m 2 ) Obese (n = 370) ( 30 kg/m 2 ) Target coronary artery, n (%) Left main 2 (1.4) 5 (1.9) 5 (1.4) 0.84 Left anterior descending 55 (37.7) 104 (40) 149 (40.3) 0.86 Left circumflex 36 (24.7) 60 (23) 89 (24.1) 0.92 Others (ramus intermedius 56 (38.4) 81 (31) 114 (30.8) 0.22 LIMA and SVG) Number of vessels involved, n (%) One 43 (29.5) 93 (35.6) 136 (36.8) 0.28 Two 49 (33.6) 88 (33.7) 111 (30) 0.55 Three 50 (34.2) 72 (27.6) 113 (30.5) 0.37 Stent type, n (%) Bare-metal 59 (40.4) 106 (40.6) 174 (47) 0.19 Drug-eluting 91 (62.3) 150 (57.5) 204 (55.1) 0.33 Multivessel intervention, n (%) 6 (4.1) 9 (3.4) 10 (2.7) 0.69 Mean peak ACT ± SD 291 ± ± ± PCI successful, n (%) 141 (96.6) 259 (99.2) 360 (97.3) 0.14 Mean number of stents 1.3 ± ± ± Hospital stay (mean ± SD in days) 2.9 ± ± ± Mean length of stent 16.3 ± ± ± Mean diameter of stent 3.0 ± ± ± LIMA = left internal mammary artery; SVG = saphenous venous graft; ACT = activated clotting time; PCI = percutaneous coronary intervention; SD = standard deviation compared to 6.1% in the overweight arm, and 5.1% in the obese arm), and the in-hospital bleeding complications were higher in the normal BMI arm (4.8% in normal BMI arm compared to 1.9% in the overweight and obese arms). All-cause mortality. After a median follow up of 4 ± 1 years, the overall mortality rate was 10.5% (82 deaths). The survival rate was 84% in the group with a normal BMI, 90% in the overweight group, and 92% in the obese group (p = by log-rank test; hazard ratio relative to the obese group was 2.2 for the normal weight and 1.2 for the overweight groups). However, after adjustment for baseline clinical and procedural characteristics (age, smoking history, chronic renal insufficiency, end-stage renal disease, left main coronary artery intervention, preprocedure hemoglobin, LVEF and successful PCI) using a Cox proportional hazards model, there was no significant difference in long-term all-cause mortality between the three groups (p = 0.93). Table 3. In-hospital outcomes. Variable Normal BMI (n = 146) (> 18.5 to < 25 kg/m 2 Over weight (n = 261) ( 25 to < 30 kg/m 2 ) Obese (n = 370) ( 30 kg/m 2 ) * Composite endpoint, % (n) 10 (6.8) 21 (8) 26 (7) 0.86 Death, % (n) Non-fatal MI, % (n) 3 (2.1) 16 (6.1) 19 (5.1) Bleeding, % (n) Any 7 (4.8) 5 (1.9) 7 (1.9) Major bleeding 4 (2.7) 2 (0.8) 3 (0.8) Minor bleeding 3 (2.1) 3 (1.1) 4 (1.1) Repeat revascularization Thrombocytopenia, % (n) 1 (0.7) 4 (1.5) 5 (1.4) *Composite endpoint includes in-hospital death, non-fatal myocardial infarction, repeat revascularization and bleeding complications; MI = myocardial infarction Vol. 21, No. 1, January
5 POLUDASU, et al. Table 4. Multivariate predictors of all-cause mortality at the end of follow-up period (4 ± 1 years). Variable Hazard Ratio 95% Confidence Interval Age Chronic renal insufficiency (creatinine > 1.5) End stage renal disease < Left ventricular ejection fraction < Left main intervention Unsuccessful PCI Baseline hemoglobin Smoking (in past 2 weeks) PCI = percutaneous coronary intervention Discussion Our study shows that in the African American population, elevated BMI is associated with reduced mortality after PCI. This apparent protective effect of higher BMI on Kaplan Meier survival analysis disappeared after adjustment for covariates with significant impact on mortality. However, overweight and obese patients having similar long-term mortality compared to normal BMI patients can still be considered an obesity paradox as one would speculate that higher BMI patients are at increased risk for long-term mortality due to the detrimental effects of obesity. We believe that the current report is the first study to evaluate the effect of BMI on long-term mortality after PCI in African-American population. A recent meta-analysis by Oreopoulos et al 5 showed that the obese patients undergoing PCI had lower short-term and longterm mortality compared to patients with normal BMI. However, this protective effect of higher BMI seemed to wear off with increasing duration of follow up. Among the studies with longer term follow up (follow-up period over 3 years), the posthoc analysis of the BARI (Bypass Angioplasty Revascularization Investigation) trial by Gurm et al 16 and the post hoc analysis of ARTS (Arterial Revascularization Therapies Study) by Gruberg et al 17 did not show any difference in long-term mortality in the obese group compared to the non-obese groups. In our study the median follow up period was 4 ± 1 years and our results are consistent with the above-referenced studies with longer-term follow up. The probable reason for not having mortality benefit in obese patients in the long-term follow-up studies compared to non-obese patients is that the better shortterm mortality after PCI in the obese group is probably offset by the adverse outcomes during the long-term follow up due to other comorbid conditions associated with obesity. An additional finding in our study is that lower BMI patients had higher mean peak ACT during the procedure and these patients had a trend towards lower non-fatal MI and higher in-hospital bleeding complications. On the other hand, higher BMI patients had lower mean peak ACT during the procedure and these patients had a trend towards higher non-fatal MI and lower in-hospital bleeding. From these findings, it can be postulated that despite weight-adjusted dosing of unfractionated heparin, higher BMI patients probably achieve subtherapuetic levels of anticoagulation during PCI and tend to have lower in-hospital bleeding complications. Recent studies suggest that bleeding complications post PCI are stronger predictors of long-term mortality compared to periprocedural MI. 15 This might partly explain the apparent protective effect of obesity on long-term mortality. This finding of higher bleeding complications in lower BMI patients was also noticed in the study by Gurm et al 3 and Powell et al. 18 Patients with higher BMI in our study were significantly younger compared to patients with lower BMI, a finding similar to other studies, 5 which could also be one of the reasons for similar long-term mortality in patients with higher BMI. Gurm et al 15 have postulated that probably large vessel size and the relatively favorable artery/device ratio could be one of the reasons for better outcomes in higher BMI patients. However, in our patient population the mean length of the stents, the mean diameter of the stents used to treat the lesions, and the procedural success rates were not significantly different between the three groups. This is a subanalysis of the data collected to evaluate the outcomes of patients undergoing PCI with a GPI bolus-only strategy. In our initial two studies on platelet GPI bolus-only with in-hospital outcomes as major endpoints, abciximab, eptifibatide and tirofiban given as a high-dose bolus (25 g/kg) had similar in-hospital ischemic endpoints. 7,8 However, patients who received abciximab as bolus-only during PCI had higher in-hospital major bleeding complications compared to the patients who received eptifibatide. 7 In the long-term follow up of the patients undergoing PCI with a bolus-only GPI strategy included in the initial two studies, abciximab was associated with higher long-term all-cause mortality at 4 ± 1 years compared to eptifibatide. Tirofiban was not significantly different from either eptifibatide or abciximab in regard to long-term mortality. 19 In the current study, the fraction of patients receiving abciximab or eptifibatide were similar but a higher proportion of patients in the normal BMI arm received tirofiban compared to the other two arms (p = for normal BMI vs. overweight patients; p < for normal BMI vs. obese patients). However, 24 The Journal of Invasive Cardiology
6 BMI and Mortality after PCI in African-Americans in our GPI bolus-only long-term follow-up study, patients who received tirofiban did not have a significant difference in longterm mortality compared to the other two agents. Also, in the multivariate analysis done in the current study, we tested the type of GPI as a covariate and found that it was not a significant predictor of long-term mortality, probably due to the smaller sample size. We believe that the GPI study might not have had any impact on the outcome of the current study. Study limitations. This study is a retrospective analysis and has all the inherent limitations of a retrospective study. Our sample size might be too small to assess the differences in longterm mortality in three subgroups. Our study population had only 9 patients with a lower BMI (underweight patients, BMI < 18.5 kg/m 2 ) and had to be excluded from the analysis, as this group could not be analyzed separately. The baseline and procedural characteristics between the three arms were reasonably similar, but there were certain differences that had to be adjusted. Despite adjustment, there could be residual confounding variables that would lead to the observed differences in outcomes between the three arms. We excluded patients with STEMI, as these patients were not included in our database. We had to exclude patients without valid Social Security numbers because we included all-cause mortality as our endpoint, which was obtained using the Social Security Death Index. 10 The exclusion of patients without Social Security numbers might have introduced a selection bias. However, all-cause mortality is considered the most unbiased endpoint in longterm outcome studies, especially if they are retrospective, as other chronic medical conditions may affect the attributed cause of death. 20,21 Despite these limitations, we conclude that BMI may not be an independent predictor of long-term all-cause mortality in African-Americans after PCI. These preliminary findings would best be confirmed in large, prospective PCI studies. References 1. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity is an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67: Minutello RM, Chou ET, Hong MK, et al. Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry). Am J Cardiol 2004;93: Gurm HS, Brennan DM, Booth J, et al. Impact of body mass index on outcome after percutaneous coronary intervention. Am J Cardiol 2002;90: Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: The obesity paradox?. J Am Coll Cardiol 2002;39: Oreopoulos A, Padwal R, Norris CM, et al. Effect of obesity on short- and long-term mortality postcoronary revascularization: A meta-analysis. Obesity (Silver Spring). 2008;16: Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, JAMA 2006;295: Marmur JD, Poludasu S, Agarwal A, et al. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 2006;18: Marmur JD, Poludasu S, Agarwal A, et al. High-dose tirofiban administered as bolus-only during percutaneous coronary intervention. J Invasive Cardiol 2008;20: Marmur JD, Poludasu S, Feit A, et al. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention. J Invasive Cardiol 2008;20: Curb JD, Ford CE, Pressel S et al. Ascertainment of vital status through the National Death Index and the Social Security Administration. Am J Epidemiol 1985; 121: Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non ST-segment elevation myocardial infarction 2002: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002;102: Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115: Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289: The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329: Lincoff AM, Kleiman NS, Kereiakes DJ, et al for the REPLACE-2 Investigators. Longterm efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs. heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292: Gurm HS, Whitlow PL, Kip KE, Investigators B. The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. J Am Coll Cardiol 2002;39: Gruberg L, Mercado N, Milo S, et al. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial. Am J Cardiol 2005;95: Powell BD, Lennon RJ, Lerman A, et al. Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol 2003;91: Marmur JD, Poludasu S, Lazar J, Cavusoglu E. Long-term mortality after bolus-only administration of abciximab, eptifibatide or tirofiban during percutaneous coronary intervention. Catheter Cardiovasc Interv (in press). 20. Gottlieb SS. Dead is dead artificial definitions are no substitute. Lancet 1997;349: Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: Time for a reassessment? J Am Coll Cardiol 1999;34: Vol. 21, No. 1, January
Clinical Investigations
Clinical Investigations Neutrophil to Lymphocyte Ratio as a Predictor of Long-term Mortality in African Americans Undergoing Percutaneous Coronary Intervention Address for correspondence: Jonathan D. Marmur,
More informationHigh-Dose Tirofiban Administered as Bolus-Only during Percutaneous Coronary Intervention
Original Contribution High-Dose Tirofiban Administered as Bolus-Only during Percutaneous Coronary Intervention Jonathan D. Marmur, MD, Shyam Poludasu, MD, Ajay Agarwal, MD, Nagarathna Manjappa MD, Erdal
More informationBolus-Only Platelet Glycoprotein IIb/IIIa Inhibition During Percutaneous Coronary Intervention
Original Contribution Bolus-Only Platelet Glycoprotein IIb/IIIa Inhibition During Percutaneous Coronary Intervention Jonathan D. Marmur, MD, Shyam Poludasu, MD, Ajay Agarwal, MD, Pompeiu Vladutiu, MD,
More informationImpact of Gender on In-Hospital Percutaneous Coronary Interventional Outcomes in African-Americans
Original Contribution Impact of Gender on In-Hospital Percutaneous Coronary Interventional Outcomes in African-Americans Shyam Poludasu, MD, Erdal Cavusoglu, MD, Luther T. Clark, MD, Jonathan D. Marmur,
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationInterventional Cardiology
Clinical Investigations Interventional Cardiology Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the
More informationLong-Term Mortality After Bolus-Only Administration of Abciximab, Eptifibatide, or Tirofiban During Percutaneous Coronary Intervention
Catheterization and Cardiovascular Interventions 73:214 221 (2009) Long-Term Mortality After Bolus-Only Administration of Abciximab, Eptifibatide, or Tirofiban During Percutaneous Coronary Intervention
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationJournal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More information6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationThe risk of death or ischemic events in patients with
Prediction of Outcome after Percutaneous Coronary Intervention for the Acute Coronary Syndrome Annapoorna S. Kini, MD, Paul C. Lee, MD, Cristina A. Mitre, MD, Michael C. Kim, MD, Mazullah Kamran, MD, Mary
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationFor Personal Use. Copyright HMP 2013
Original Contribution Impact of Peripheral Vascular Disease on Short- and Long-term Outcomes in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention in the Drug-Eluting Stent Era Scott Midwall,
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationbivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company
bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company 06 August 2010 The Scottish Medicines Consortium (SMC) has completed its
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationImpact of Body Mass Index on In-Hospital Outcomes after Percutaneous Coronary Intervention
PERCUTANEOUS CORONARY INTERVENTION ORIGINAL RESEARCH Impact of Body Mass Index on In-Hospital Outcomes after Percutaneous Coronary Intervention Bahram Sohrabi MD 1, Afshin Habibzadeh MD 1, Samad Ghaffari
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationA Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS
Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationBivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationTarget vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI
Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI Gamal Abdelhady, Emad Mahmoud Department of interventional
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationClinical Lessons from BMC2-PCI
Clinical Lessons from BMC2-PCI The Blue Cross Blue Shield of Michigan Cardiovascular Consortium Hitinder Gurm, M.D. University of Michigan Overview 32 papers since inception 10 papers published this year
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More information4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin, 250mg powder for concentrate for solution for injection or infusion (Angiox ) No. (516/08) The Medicines Company UK Ltd 07 November 2008 The Scottish Medicines
More informationJournal of the American College of Cardiology Vol. 44, No. 9, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, No. 9, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.05.085
More informationIncidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction
Incidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction Sungmin Lim, Yoon Seok Koh, Hee Yeol Kim, Ik Jun Choi, Eun Ho Choo, Jin Jin Kim, Mineok
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationUnstable angina and NSTEMI
Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More information10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationInternational Journal of Collaborative Research on Internal Medicine & Public Health (IJCRIMPH)
Same-day discharge after percutaneous coronary intervention in light of the society for cardiovascular angiography and intervention's proposed guidelines: A single-center experience Yazan Khouri, Sachin
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More informationAcute coronary syndromes (ACS), including unstable
n report n Acute Coronary Syndromes: Morbidity, Mortality, and Pharmacoeconomic Burden Daniel M. Kolansky, MD Abstract Acute coronary syndromes (ACS), which include unstable angina and myocardial infarction
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationDisclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None
Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines
More informationProspective Comparison of Hemorrhagic Complications After Treatment With Enoxaparin
Prospective Comparison of Hemorrhagic Complications After Treatment With Versus Unfractionated Heparin for Unstable Angina Pectoris or Non ST-Segment Elevation Acute Myocardial Infarction Scott D. Berkowitz,
More informationINTRODUCTION. Key Words:
Original Article Acta Cardiol Sin 2017;33:377 383 doi: 10.6515/ACS20170126A Percutaneous Coronary Intervention Predictors of Mortality in Elderly Patients with Non-ST Elevation Acute Coronary Syndrome
More informationAsian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationKorea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea
Left Main Disease versus Non Left Main Disease in Acute Myocardial Infarction Patients in Real world Clinical Practice : Lessons from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha*,
More informationIs the role of bivalirudin established?
Is the role of bivalirudin established? Rob Henderson Consultant Cardiologist Trent Cardiac Centre Nottingham University Hospitals Conflicts of Interest: None Declarations: Member NICE Unstable Angina
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationCoronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy
Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationSupplementary Table 1: Age, gender and treatment received in included studies
Supplementary Table 1: Age, gender and treatment received in included studies Study ID Mean age % male Therapies received Amlani 2010 [32] 62 80 Aspirin 99%, clopidogrel 99%, enoxaparin 17%, unfractionated
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationRisk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium
Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Case Presentation 46 year old
More informationS PECIAL A RTICLE. Combination Antiplatelet Therapy: Implications for Pharmacists
S PECIAL A RTICLE Combination Antiplatelet Therapy: Implications for Pharmacists Robert L. Talbert, Pharm.D., FCCP, Sarah A. Spinler, Pharm.D., FCCP, Jean M. Nappi, Pharm.D., FCCP, and Michael B. Bottorff,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationOutcomes With the Paclitaxel-Eluting Stent in Patients With Acute Coronary Syndromes Analysis From the TAXUS-IV Trial
Journal of the American College of Cardiology Vol. 45, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.10.074
More informationStatin pretreatment and presentation patterns in patients with acute coronary syndromes
Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationTreatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement
Treatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement Pharmaceutical Care Project Outcomes Literature Evaluation
More information